ZAI LAB LIMITED

ZLAB ·Healthcare, Drug Manufacturers - General
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $-175.5M $-257.1M $-334.6M $-443.3M $-704.5M $-268.9M $-195.1M $-139.1M
Depreciation & Amortization $15.0M $11.9M $9.0M $8.2M $6.5M $4.6M $3.8M $1.7M
Depreciation $9.1M $8.6M $8.4M $7.7M $6.0M $4.3M $3.4M $4.3M
Amortization $5.9M $3.2M $700.0K $500.0K $500.0K $300.0K $305.0K $15.0K
Stock-Based Compensation $65.6M $70.7M $79.6M $61.3M $40.7M $24.8M $20.3M $12.2M
Net Cash from Operating Activities $-150.8M $-214.9M $-198.2M $-367.6M $-549.2M $-216.1M $-191.0M $-97.5M
Investing Activities
Capital Expenditures $8.1M $5.7M $7.2M $24.6M $18.3M $10.1M $6.0M $10.0M
Business Acquisitions
Net Cash from Investing Activities $307.9M $-375.2M $-10.8M $420.0M $250.0M $-554.8M $-14.9M $-212.6M
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $72.4M $349.9M $-6.4M $-1.7M $820.2M $1.13B $219.3M $144.1M
Net Change in Cash $229.9M $-240.5M $-218.0M $44.4M $522.0M $366.4M $13.5M $-166.7M
Free Cash Flow $-158.9M $-220.5M $-205.4M $-392.2M $-567.5M $-226.2M $-197.0M $-107.6M